Vertex Pharmaceuticals (VRTX) Notes Payables (2016 - 2017)
Vertex Pharmaceuticals' quarterly Notes Payables came in at $232.4 million in Q4 2017, up 216.55% year-on-year from $73.4 million in Q4 2016, and up 22.14% quarter-over-quarter from $190.3 million in Q3 2017.
Vertex Pharmaceuticals has reported Notes Payables for 2 years, with the latest figure at $232.4 million in Q4 2017.
- For the quarter ending Q4 2017, Notes Payables rose 216.55% year-over-year to $232.4 million; the trailing twelve-month figure through Dec 2017 stood at $232.4 million (up 216.55% YoY), and the FY2017 full-year result was $232.4 million, up 216.55% from the prior year.
- Notes Payables for Q4 2017 stood at $232.4 million, up from $190.3 million in the prior quarter.
- The five-year high for Notes Payables was $232.4 million in Q4 2017, with the low at $73.4 million in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 232.40 Mn |
| Sep 30, 2017 | 190.27 Mn |
| Jun 30, 2017 | 147.69 Mn |
| Mar 31, 2017 | 104.77 Mn |
| Dec 31, 2016 | 73.42 Mn |